An Open Label, Randomised Phase II Study Assessing Quality of Life Associated With Subcutaneous Trastuzumab Injected Into the Thigh or Upper Arm in Patients With HER2-positive Early Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2014
Price : $35 *
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms LISAH
- Sponsors Roche
- 03 Mar 2014 According to the the ClinicalTrials.gov record, status changed from suspended to discontinued.
- 16 Nov 2013 Status changed from completed to suspended as reported by European Clinical Trials Database.
- 16 Oct 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.